AI in drug discovery

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Three more pharmas join OpenFold3 AI consortium

Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.

News

MSD's $345m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

Lilly offers AI discovery models to biotech partners

Eli Lilly is offering AI-powered drug discovery models developed at a cost of around $1 billion to biotech companies for free.

R&D

The impact of generative AI on protein design for drug disco...

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

R&D

pharmaphorum podcast Episode 191a, Ben Sidders

Ben Sidders on integrating causality in AI for R&D success

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

Ignota vacuums up Kronos Bio's drug programmes

Three more pharmas join OpenFold3 AI consortium

MSD's $345m alliance with Variational, and other AI news

Lilly offers AI discovery models to biotech partners

The impact of generative AI on protein design for drug disco...

Ben Sidders on integrating causality in AI for R&D success

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AI in drug discovery

Editor's Picks